Your shopping cart is currently empty

BMS 275183 is a potent, orally active analogue of Paclitaxel. It stabilizes microtubules and exhibits antitumor activity in in vivo tumor models. BMS 275183 is also effective in vitro against Paclitaxel-resistant tumors, including those with tubulin mutations or overexpression of P-glycoprotein. It is applicable in cancer research, such as in non-small cell lung cancer (NSCLC) and prostate cancer studies.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | BMS 275183 is a potent, orally active analogue of Paclitaxel. It stabilizes microtubules and exhibits antitumor activity in in vivo tumor models. BMS 275183 is also effective in vitro against Paclitaxel-resistant tumors, including those with tubulin mutations or overexpression of P-glycoprotein. It is applicable in cancer research, such as in non-small cell lung cancer (NSCLC) and prostate cancer studies. |
| Molecular Weight | 845.94 |
| Formula | C43H59NO16 |
| Cas No. | 355113-98-3 |
| Smiles | O(C(OC)=O)[C@]12[C@]3([C@H](OC(=O)C4=CC=CC=C4)[C@@]5(O)C(C)(C)C([C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@]1(OC2)[H])=C(C)[C@@H](OC([C@@H]([C@@H](NC(OC(C)(C)C)=O)C(C)(C)C)O)=O)C5)[H] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.